The Third Xiangya Hospital of Central South University
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China18 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines | Moderate to Severe Glabellar Lines | Recruiting | Phase 3 | 2026-09-23 | NCT06937944 | |
| ASPIrin in Reducing Events in Dialysis ( ASPIRED ) | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Active, not recruiting | Phase 4 | 2026-09-14 | NCT04381143 | |
| Phase 3 Study to Evaluate the Efficacy and Safety of Human Growth Hormone Injection (Sinotropin AQ) for the Treatment of Children With Idiopathic Short Stature | Idiopathic Short Stature (ISS) | Not yet recruiting | Phase 3 | 2026-09-11 | NCT07815626 | |
| A Clinical Study of Cizutamig in Thyroid Eye Disease | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases, Hereditary, Graves Ophthalmopathy, Graves disease, autoimmune disease, disease of orbital part of eye adnexa, endocrine system disorder, exophthalmos, eye disorder, goiter, hereditary disease, hyperthyroidism, immune system disorder, thyroid gland disorder | Recruiting | Phase 1 | 2026-09-01 | NCT07597200 | |
| Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis | Skin Diseases, Eczematous, Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, dermatitis, sebaceous gland disorder, seborrheic dermatitis, skin disorder | Not yet recruiting | Phase 3 | 2026-08-21 | NCT07683806 | |
| A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Active, not recruiting | Phase 3 | 2026-07-30 | NCT04194775 | |
| Digital Mindfulness-Based Therapy for Obsessive-Compulsive Disorder | anxiety disorder, obsessive-compulsive disorder, psychiatric disorder | Recruiting | Not applicable | 2026-07-20 | NCT07701616 | |
| Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA) | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Recruiting | Phase 2 | 2026-07-01 | NCT07265570 | |
| Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Disease Progression, Neoplasms by Site, Pancreatic cancer, adult, Pathologic Processes, Pathological Conditions, Signs and Symptoms, anxiety disorder, benign neoplasm of pancreas, depressive disorder, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm, psychiatric disorder | Recruiting | Not stated | 2026-06-29 | NCT07529626 | |
| A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Abdominal Surgery | Pain After Surgery | Recruiting | Phase 2 | 2026-05-28 | NCT07533786 | |
| HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia | Warm Antibody Autoimmune Hemolytic Anemia | Active, not recruiting | Phase 2 / Phase 3 | 2026-05-18 | NCT05535933 | |
| Evaluation of Chiglitazar Sodium With Lifestyle Intervention for Reversing Prediabetes | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose intolerance, glucose metabolism disease, hyperglycemia, metabolic disease, prediabetes syndrome | Not yet recruiting | Not applicable | 2026-04-30 | NCT07558525 | |
| Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Pain Management in Abdominal Surgery | Moderate to Severe Acute Postoperative Pain | Recruiting | Phase 2 | 2025-12-30 | NCT07311369 | |
| A Study of Telitacicept for IgA Nephropathy (TELIGAN) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, nephritis, urinary system disorder | Active, not recruiting | Phase 3 | 2025-12-16 | NCT05799287 | |
| A Study to Evaluate Features of KN069 in Participants With Obesity or Overweight | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 1 | 2025-09-17 | NCT06547775 | |
| A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Nutritional and Metabolic Diseases, familial hypercholesterolemia, hereditary disease, hyperlipidemia, hyperlipoproteinemia, inborn errors of metabolism, metabolic disease | Recruiting | Phase 3 | 2025-02-06 | NCT06568471 | |
| A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Chinese Healthy Male Subjects | Healthy Subjects (HS) | Not yet recruiting | Phase 1 | 2024-10-15 | NCT06641388 | |
| An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 4 | 2023-11-09 | NCT05908695 |